A phase 3, double-blind, placebo-controlled multicenter study of the effectiveness and safety of an oral investigational study medication in patients with Nonalcoholic Steatohepatitis (NASH).
Enrollment Status: OPEN
This is a phase 3 research study for patients with NASH (Nonalcoholic Steatohepatitis) who have evidence of liver fibrosis. Participants will remain on the study and continue to receive the study investigational medication or placebo until the study is completed. It is estimated that patients will participate for a minimum of approximately 6 years. During this time, participants will be evaluated by the study team after the first month of treatment and then once every three months through Month 18. Following the Month 18 visit, participants will be evaluated two times per year (every six-months) for each additional year in the study.
For more information, call 612-870-5599 or visit www.NASH-study.com.
For more information or eligibility criteria, call our Research Hotline number at 612-870-5599, OR input the following information and we will follow up with you to discuss your interest: